Celltrion to directly sell Remsima SC, secure global distribution network

[THE INVESTOR] Korea’s leading biosimilar firm Celltrion will establish a direct sales network for its drugs worldwide, namely for its Remsima SC — a subcutaneous version of Remsima – in an effort to secure price competitiveness and lead the global biosimilar market, its chief said in a New Year’s press conference last week. The firm …

Celltrion to directly sell Remsima SC, secure global distribution network Read More »